From next week, any company applying to produce a new medicine or extendthe licence for an existing one must demonstrate that the drug can alsobe used for children, unless they can show there is no demand forit.
Manufacturers developing medicines specifically for children will haveto conduct trials with them before their applications are cleared. Toencourage companies to develop children's medicines, firms will getmarket exclusivity for six months, or two years for rarer medicines.
A paediatric committee of experts will be established by the EU in Julyto vet companies' plans and to ensure a focus is placed on developingmedicines that children most need.
Professor Imtiaz Choonara, professor in child health at the Universityof Nottingham, said there was "tremendous potential" to develop newmedicines.
Register Now to Continue Reading
Thank you for visiting Children & Young People Now and making use of our archive of more than 60,000 expert features, topics hubs, case studies and policy updates. Why not register today and enjoy the following great benefits:
What's Included
-
Free access to 4 subscriber-only articles per month
-
Email newsletter providing advice and guidance across the sector
Already have an account? Sign in here
